Carbidopa HCl | CAS# 65132-60-7 (HCl) | Parkinson's disease

MedKoo Cat#: 412303 | Name: Carbidopa HCl

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Carbidopa hydrochloride is a drug given to people with Parkinson's disease in order to inhibit peripheral metabolism of levodopa. This property is significant in that it allows a greater proportion of peripheral levodopa to cross the blood–brain barrier for central nervous system effect.

Chemical Structure

Carbidopa HCl

CAS#65132-60-7 (HCl)

Theoretical Analysis

MedKoo Cat#: 412303

Name: Carbidopa HCl

CAS#: 65132-60-7 (HCl)

Chemical Formula: C10H15ClN2O4

Exact Mass: 0.0000

Molecular Weight: 262.69

Elemental Analysis: C, 45.72; H, 5.76; Cl, 13.49; N, 10.66; O, 24.36

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

38821-49-7 (hydrate) 28860-95-9 (anhydrous) 65132-60-7 (HCl)

Synonym

Carbidopa hydrochloride; Carbidopa HCl

IUPAC/Chemical Name

(S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid hydrochloride

InChi Key

FRTJEAIOPNOZNI-PPHPATTJSA-N

InChi Code

InChI=1S/C10H14N2O4.ClH/c1-10(12-11,9(15)16)5-6-2-3-7(13)8(14)4-6;/h2-4,12-14H,5,11H2,1H3,(H,15,16);1H/t10-;/m0./s1

SMILES Code

C[C@@](NN)(C(O)=O)Cc1cc(O)c(O)cc1.Cl

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 262.69 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Calandra-Buonaura G, Doria A, Lopane G, Guaraldi P, Capellari S, Martinelli P, Cortelli P, Contin M. Pharmacodynamics of a low subacute levodopa dose helps distinguish between multiple system atrophy with predominant Parkinsonism and Parkinson's disease. J Neurol. 2015 Nov 14. [Epub ahead of print] PubMed PMID: 26566913. 2: Zhang D, McGregor M, Bordia T, Perez XA, McIntosh JM, Decker MW, Quik M. α7 nicotinic receptor agonists reduce levodopa-induced dyskinesias with severe nigrostriatal damage. Mov Disord. 2015 Nov 17. doi: 10.1002/mds.26453. [Epub ahead of print] Review. PubMed PMID: 26573698. 3: Battista JP, Greene PE. Improvement of Primary Writing Tremor in Parkinson's Disease with Carbidopa/Levodopa. Tremor Other Hyperkinet Mov (N Y). 2015 Oct 22;5:345. doi: 10.7916/D8WQ035T. eCollection 2015. PubMed PMID: 26566458; PubMed Central PMCID: PMC4636028.